Study wrapper · #1092
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
Editor's note
This narrative review pulls together randomized and observational evidence linking semaglutide to reduced alcohol-related outcomes, with weaker signals for tobacco and other substances. As a synthesis rather than primary data, it reflects an evolving and still-uncertain evidence base, and tirzepatide-specific data are noted as preliminary. Regard the alcohol association as the most substantiated of the behaviors discussed.
Plain-language abstract
This review synthesizes emerging evidence that incretin therapies, especially semaglutide, are associated with reduced alcohol use and, more tentatively, reduced tobacco and other substance use. The alcohol signal is described as the strongest, while tirzepatide-specific and other-substance evidence remains preliminary.